Frontiers reaches 6.4 on Journal Impact Factors

General Commentary ARTICLE

Front. Oncol., 22 April 2014 | https://doi.org/10.3389/fonc.2014.00083

Corrigendum: Involvement of a non-human sialic acid in human cancer

imageAnnie N. Samraj, imageHeinz Läubli, imageNissi Varki and imageAjit Varki*
  • Departments of Medicine, Pathology and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA

A corrigendum on

Involvement of a non-human sialic acid in human cancer
by Samraj AN, Läubli H and Varki A. Front Oncol (2014) 4:33. doi: 10.3389/fonc.2014.00033

Antibodies 14F7 and the corresponding anti-idiotype 1E10 (racotumomab, misspelled as racotumumab) were mistakenly conflated in this review. 14F7 reacts with (Neu5Gc)GM3, was recently humanized (1), but has not yet been tested in clinical trials. Racotumomab induced a human anti-(Neu5Gc)GM3 immune response, which correlated with longer median survival in non-small cell lung cancer (2). The first clinical trial result using racotumomab was actually published in 2002 (3). A phase III trial testing racotumomab in advanced non-small cell lung cancer began in 2011, and is currently recruiting (NCT01460472). These studies do not consider dietary Neu5Gc intake and incorporation as a variable that could affect (Neu5Gc)GM3 expression by human cancers.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Fernández-Marrero Y, Roque-Navarro L, Hernández T, Dorvignit D, Molina-Pérez M, González A, et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology (2011) 216:1239–47. doi:10.1016/j.imbio.2011.07.004

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

2. Hernández AM, Toledo D, Martínez D, Griñán T, Brito V, Macías A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol (2008) 181:6625–34.

Pubmed Abstract | Pubmed Full Text

3. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol (2002) 168:2523–9.

Pubmed Abstract | Pubmed Full Text

Keywords: Neu5Gc, sialic acid, antibodies, inflammation, tumor antigen, red meat

Citation: Samraj AN, Läubli H, Varki N and Varki A (2014) Corrigendum: Involvement of a non-human sialic acid in human cancer. Front. Oncol. 4:83. doi: 10.3389/fonc.2014.00083

Received: 02 April 2014; Accepted: 04 April 2014;
Published online: 22 April 2014.

Edited and reviewed by: Adriane Regina Todeschini, Universidade Federal do Rio de Janeiro, Brazil

Copyright: © 2014 Samraj, Läubli, Varki and Varki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: a1varki@ucsd.edu